Skip to content

Study · Randomized controlled trial · 2016

4 results

Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.

Kim ED, McCullough A, Kaminetsky J

BJU international23 Oct 2015Cited by 54 (Europe PMC)

PMID26496621 (opens in a new tab)DOI10.1111/bju.13337 (opens in a new tab)PepBankPUB-26496621
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight hypogonadal men, enclomiphene increased FSH while testosterone gel decreased it.

    In plain wordsIn overweight hypogonadal men, FSH rose with enclomiphene and fell with testosterone gel.

    Peptide
    Enclomiphene
    Outcome
    IncreaseFSH
    Study

    n: not reported in source

    Comparator
    Testosterone gel
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · oral · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    FSH and LH levels increased in the enclomiphene citrate groups and decreased in the testosterone gel group at 16 weeks.
    1 context sentence
    Summary · context
    Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel (AndroGel(®) 1.62%) on TT, LH, FSH, and sperm counts in overweight men aged 18-60 years with secondary hypogonadism.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight hypogonadal men, enclomiphene increased LH while testosterone gel decreased it.

    In plain wordsIn overweight hypogonadal men, LH rose with enclomiphene and fell with testosterone gel.

    Peptide
    Enclomiphene
    Outcome
    IncreaseLH
    Study

    n: not reported in source

    Comparator
    Testosterone gel
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · oral · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    FSH and LH levels increased in the enclomiphene citrate groups and decreased in the testosterone gel group at 16 weeks.
    1 context sentence
    Summary · context
    Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel (AndroGel(®) 1.62%) on TT, LH, FSH, and sperm counts in overweight men aged 18-60 years with secondary hypogonadism.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight hypogonadal men, enclomiphene maintained normal sperm concentration while testosterone gel markedly reduced spermatogenesis.

    In plain wordsIn overweight hypogonadal men, enclomiphene maintained normal sperm concentration, while testosterone gel reduced sperm production.

    Peptide
    Enclomiphene
    Outcome
    No significant changeSperm concentration
    Study

    n: not reported in source

    Comparator
    Testosterone gel
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · oral · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Enclomiphene citrate maintained sperm concentration in the normal range over the treatment period, while there was a marked reduction in spermatogenesis in the testosterone gel group.
    1 context sentence
    Summary · context
    Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel (AndroGel(®) 1.62%) on TT, LH, FSH, and sperm counts in overweight men aged 18-60 years with secondary hypogonadism.

Studies that did not test the peptide alone1

In this study, Enclomiphene was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Enclomiphene.

  1. 04HumanNot a test of Enclomiphene aloneRandomized controlled trialEfficacy outcome

    In overweight hypogonadal men, testosterone increased in all treatment groups, without an isolated enclomiphene effect in this result.

    In plain wordsIn overweight hypogonadal men, testosterone rose in all treatment groups.

    Peptide
    Enclomiphene
    Outcome
    IncreaseTotal testosterone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    TT levels increased between baseline and after 16 weeks of treatment in all the treatment groups.
    1 context sentence
    Summary · context
    Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel (AndroGel(®) 1.62%) on TT, LH, FSH, and sperm counts in overweight men aged 18-60 years with secondary hypogonadism.

    In this study, Enclomiphene was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Enclomiphene.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.